In continuation of the company's announcement on 3 November 1999 of a planned stock repurchasing programme, and pursuant to Section 204.33, Treasury Stock Changes, of the New York Stock Exchange Listed Company Manual, and to Section 28 of the Danish Securities Trading Act, this is to report that as of today, Novo Nordisk A/S (NYSE: NVO) owns 6,035,309 B shares, corresponding to 8.00% of the total capital stock.
Novo Nordisk A/S is the world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzymes. Headquartered in Denmark, Novo Nordisk employs approximately 15,000 people in 61 countries and markets its products in 179 countries. Its B shares are listed on the stock exchanges in Copenhagen, London and Zurich. Its ADSs are listed on the New York Stock Exchange under the symbol "NVO". For further company information, visit Novo Nordisk on the World Wide Web at www.novo.dk.
For further information please contact:
Communications & Design
Media:
Elin K Hansen
Phone (direct) : (+45) 4442 3450
Elin K Hansen
Phone (direct) : (+45) 4442 3450
Media in North America:
Susan Toth Jackson
Phone: (+1) 212-867-0123
Susan Toth Jackson
Phone: (+1) 212-867-0123
Investors:
Michael Steen-Knudsen
Phone (Direct): (+45) 4442 6048
Michael Steen-Knudsen
Phone (Direct): (+45) 4442 6048